SCHEMBL2214950

SCHEMBL2214950

NCc1ccc(C(=O)Nc2ccc(Nc3nc(-c4ccc(-c5ccccc5)nc4)cc4ccnn34)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.46
PTPN2 P17706 1/20 0.46
TRPV1 Q8NER1 2/20 0.43
KIT P10721 1/20 0.43
PDGFRA P16234 1/20 0.43
PTPN6 P29350 1/20 0.41
PTPN11 Q06124 1/20 0.41
SIRT2 Q8IXJ6 2/20 0.41
SIRT1 Q96EB6 2/20 0.41
SIRT3 Q9NTG7 2/20 0.41
MCHR1 Q99705 1/20 0.41
HDAC1 Q13547 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
LOXL2 Q9Y4K0 3/20 0.39
LOX P28300 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
JAK2 O60674 1/20 0.39
PLAU P00749 2/20 0.38
F2 P00734 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211981 0.94 HDAC1 (0.45) PTPN1KITPDGFRAHDAC1NR1H4
SCHEMBL2214589 0.90 HDAC1 (0.45) KITPDGFRAHDAC1NR1H4LOXL2
SCHEMBL2214363 0.88 HDAC1 (0.42) PTPN1KITPDGFRAPTPN6PTPN11
SCHEMBL2215216 0.87 PLAU (0.41) TRPV1KITPDGFRAHDAC1LOXL2
SCHEMBL2215297 0.86 PTPN1 (0.45) PTPN1PTPN2PTPN6PTPN11MCHR1
SCHEMBL2215236 0.86 HDAC1 (0.41) KITPDGFRAHDAC1LOXL2MEN1
SCHEMBL2213295 0.85 NAMPT (0.49) PTPN1PTPN2TRPV1HDAC1
SCHEMBL2215002 0.85 JAK2 (0.45) KITPDGFRASIRT2SIRT1SIRT3
SCHEMBL2215189 0.85 PLAU (0.50) TRPV1LOXL2LOXMEN1KMT2A
SCHEMBL2214781 0.84 CREBBP (0.42) KITPDGFRAPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 PTPN1 2322/4885PTPN2 1981/4885TRPV1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.